Intended for healthcare professionals

Rapid response to:

Editorials

Statins and The BMJ

BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5038 (Published 07 August 2014) Cite this as: BMJ 2014;349:g5038

Rapid Response:

Individual level data from big pharma

As an independent researcher and a PhD student who focuses on the statin safety in older adults aged 65 years and older in primary prevention, I have applied two datasets (APSEN & BONE) from Pfizer and one dataset from Astrazenaca (METEOR). Both of them were willing and friendly to share the individual patient data, even the access process took me around 1-2 years.

Thankfully, I also got access to PREVENT-IT data from Dr. Frank. Furthermore, I know that Pfizer are also willing to share other data they have, such as ASCOT-LLA data. I will be very glad to share these unpublished data in my meta-analysis which is estimated to be submitted at the end of this year.

Considering my experience, it seems unfair to claim that big pharma are unwilling to disclose the data from the trial they sponsored.

Competing interests: No competing interests

16 September 2018
Zhen Zhou
PhD candidate
Menzies Institute for Medical Research, University of Tasmania
17 Liverpool street, Hobart, TAS7000, Australia